The University of Southampton
University of Southampton Institutional Repository

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive/advanced cancer of the urothelium (RISC)

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive/advanced cancer of the urothelium (RISC)
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive/advanced cancer of the urothelium (RISC)

Background

Cisplatin-based combination chemotherapy is the standard treatment for advanced urinary tract cancer (aUTC) but 50% of patients are ineligible for cisplatin according to recently published criteria. We used a multinational database to study patterns of chemotherapy utilization in patients with aUTC and determine their impact on survival.

Patients and Methods

This was a retrospective study of patients with: UTC (bladder, renal pelvis, ureter or urethra); advanced disease (stages T4b and/or N+ and/or M+); urothelial, squamous or adenocarcinoma histology. Primary objective was overall survival (OS). Eligibility-for-cisplatin was defined by: Eastern Cooperative Oncology group (ECOG) performance status (PS)≤1, creatinine clearance (CrCl)≥60 ml/min, no hearing loss, no neuropathy, no heart failure. Cox regression multivariate analyses were used to establish independent associations of cisplatin vs. non-cisplatin-based chemotherapy on OS.

Results

About 1794 patients treated between 2000 and 2013 at 29 centers were analyzed. Median follow-up was 29.1 months. 1333 patients (74%) received 1st-line chemotherapy: Use of 1st-line chemotherapy was associated with longer OS: (Hazard ratio [HR]: 1.91, 95% confidence interval [CI]: 1.67-2.20). Type of 1st-line chemotherapy received was: cisplatin-based 669 (50%), carboplatin-based 399 (30%), other 265 (20%). Cisplatin use was an independent favorable prognostic factor (HR: 1.54, 95% CI: 1.35-1.77). This benefit was independent of baseline characteristics or co-morbidities but was associated with eligibility-for-cisplatin: eligible patients treated with cisplatin lived longer than those who were not (HR: 1.74, 95% CI: 1.36-2.21), while such benefit was not observed among ineligible patients. 26% of patients who did not receive cisplatin were eligible for this agent. Median OS of ineligible patients was poor irrespective of the chemotherapy used.

Conclusions

The importance of applying published criteria of eligibility-for-cisplatin was confirmed in a multinational, real-world setting in aUTC. The reasons for deviations from these criteria set targets to improve adherence. Effective therapies for cisplatin-ineligible patients are needed.

Journal Article
1569-8041
361–369
Bamias, A.
adfc02a4-8013-4cb8-9449-7948af82f0be
Tzannis, K.
6b8ec4bb-7af7-4d3d-8400-7038a0706b1d
Harshman, L.C.
43988992-3898-4e8c-a766-e8320281bdcf
Crabb, S.J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Wong, Y.-N.
baf9fa8e-9ca4-4e76-85ae-0e96eff399a6
Pal, S. Kumar
e32d8dc8-4d4c-49e4-84bd-84043bb7dfb9
De Giorgi, U.
4faf9b0b-4122-4baf-8de2-68683af2451c
Ladoire, S.
565703f0-69eb-4976-a49f-d6461e9bcb93
Agarwal, N.
0f0a8621-5cef-4fcc-874d-d1ed32898bf5
Yu, E.Y.
63dbe6f2-a2c2-4535-a0e7-8c1e9de017b5
Niegisch, G.
7edd128e-cc2e-4bce-ae7d-8dd6352bcffd
Necchi, A.
b274fd73-d3f3-4cc8-9329-5dfde8759265
Sternberg, C.N.
914f349e-0766-4f5a-b32d-3f9b9cc1c24d
Srinivas, S.
731405dc-922a-40c0-9b1e-af356cdec141
Alva, A.
1cb3570b-3218-4ef3-861d-6796299d153c
Vaishampayan, U.
7ffdb090-8d7b-4363-b3cf-1632d219ba26
Cerbone, L.
d1fcdcd4-35a0-47a4-afc2-8dd72f26ee32
Liontos, M.
db79f34c-11dd-4a40-9ca2-b02de1adba04
Rosenberg, J.
57af5465-dce9-4ee4-8bc6-1774623b4349
Powles, T.
0d3f760a-49dd-46f1-b94d-abb7d0b9ae6d
Belmunt, J.
c2f6162b-ad97-4da7-ad9f-fdfed0eb5f5d
Galsky, M.D.
559dd6c8-db20-4e44-ab18-0bfaa4b349cb
RISC Investigators
Bamias, A.
adfc02a4-8013-4cb8-9449-7948af82f0be
Tzannis, K.
6b8ec4bb-7af7-4d3d-8400-7038a0706b1d
Harshman, L.C.
43988992-3898-4e8c-a766-e8320281bdcf
Crabb, S.J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Wong, Y.-N.
baf9fa8e-9ca4-4e76-85ae-0e96eff399a6
Pal, S. Kumar
e32d8dc8-4d4c-49e4-84bd-84043bb7dfb9
De Giorgi, U.
4faf9b0b-4122-4baf-8de2-68683af2451c
Ladoire, S.
565703f0-69eb-4976-a49f-d6461e9bcb93
Agarwal, N.
0f0a8621-5cef-4fcc-874d-d1ed32898bf5
Yu, E.Y.
63dbe6f2-a2c2-4535-a0e7-8c1e9de017b5
Niegisch, G.
7edd128e-cc2e-4bce-ae7d-8dd6352bcffd
Necchi, A.
b274fd73-d3f3-4cc8-9329-5dfde8759265
Sternberg, C.N.
914f349e-0766-4f5a-b32d-3f9b9cc1c24d
Srinivas, S.
731405dc-922a-40c0-9b1e-af356cdec141
Alva, A.
1cb3570b-3218-4ef3-861d-6796299d153c
Vaishampayan, U.
7ffdb090-8d7b-4363-b3cf-1632d219ba26
Cerbone, L.
d1fcdcd4-35a0-47a4-afc2-8dd72f26ee32
Liontos, M.
db79f34c-11dd-4a40-9ca2-b02de1adba04
Rosenberg, J.
57af5465-dce9-4ee4-8bc6-1774623b4349
Powles, T.
0d3f760a-49dd-46f1-b94d-abb7d0b9ae6d
Belmunt, J.
c2f6162b-ad97-4da7-ad9f-fdfed0eb5f5d
Galsky, M.D.
559dd6c8-db20-4e44-ab18-0bfaa4b349cb

Bamias, A., Tzannis, K., Harshman, L.C., Crabb, S.J., Wong, Y.-N., Pal, S. Kumar, De Giorgi, U., Ladoire, S., Agarwal, N., Yu, E.Y., Niegisch, G., Necchi, A., Sternberg, C.N., Srinivas, S., Alva, A., Vaishampayan, U., Cerbone, L., Liontos, M., Rosenberg, J., Powles, T., Belmunt, J. and Galsky, M.D. , RISC Investigators (2018) Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive/advanced cancer of the urothelium (RISC). Annals of Oncology, 29 (2), 361–369. (doi:10.1093/annonc/mdx692).

Record type: Article

Abstract

Background

Cisplatin-based combination chemotherapy is the standard treatment for advanced urinary tract cancer (aUTC) but 50% of patients are ineligible for cisplatin according to recently published criteria. We used a multinational database to study patterns of chemotherapy utilization in patients with aUTC and determine their impact on survival.

Patients and Methods

This was a retrospective study of patients with: UTC (bladder, renal pelvis, ureter or urethra); advanced disease (stages T4b and/or N+ and/or M+); urothelial, squamous or adenocarcinoma histology. Primary objective was overall survival (OS). Eligibility-for-cisplatin was defined by: Eastern Cooperative Oncology group (ECOG) performance status (PS)≤1, creatinine clearance (CrCl)≥60 ml/min, no hearing loss, no neuropathy, no heart failure. Cox regression multivariate analyses were used to establish independent associations of cisplatin vs. non-cisplatin-based chemotherapy on OS.

Results

About 1794 patients treated between 2000 and 2013 at 29 centers were analyzed. Median follow-up was 29.1 months. 1333 patients (74%) received 1st-line chemotherapy: Use of 1st-line chemotherapy was associated with longer OS: (Hazard ratio [HR]: 1.91, 95% confidence interval [CI]: 1.67-2.20). Type of 1st-line chemotherapy received was: cisplatin-based 669 (50%), carboplatin-based 399 (30%), other 265 (20%). Cisplatin use was an independent favorable prognostic factor (HR: 1.54, 95% CI: 1.35-1.77). This benefit was independent of baseline characteristics or co-morbidities but was associated with eligibility-for-cisplatin: eligible patients treated with cisplatin lived longer than those who were not (HR: 1.74, 95% CI: 1.36-2.21), while such benefit was not observed among ineligible patients. 26% of patients who did not receive cisplatin were eligible for this agent. Median OS of ineligible patients was poor irrespective of the chemotherapy used.

Conclusions

The importance of applying published criteria of eligibility-for-cisplatin was confirmed in a multinational, real-world setting in aUTC. The reasons for deviations from these criteria set targets to improve adherence. Effective therapies for cisplatin-ineligible patients are needed.

Text
Bamias et al_clean 24032017 - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (78kB)

More information

Accepted/In Press date: 25 October 2017
e-pub ahead of print date: 25 October 2017
Published date: 1 February 2018
Additional Information: © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Keywords: Journal Article

Identifiers

Local EPrints ID: 418654
URI: https://eprints.soton.ac.uk/id/eprint/418654
ISSN: 1569-8041
PURE UUID: b34d800b-cfdf-464f-9e2c-f087400df2dc

Catalogue record

Date deposited: 14 Mar 2018 17:30
Last modified: 14 Mar 2019 05:26

Export record

Altmetrics

Contributors

Author: A. Bamias
Author: K. Tzannis
Author: L.C. Harshman
Author: S.J. Crabb
Author: Y.-N. Wong
Author: S. Kumar Pal
Author: U. De Giorgi
Author: S. Ladoire
Author: N. Agarwal
Author: E.Y. Yu
Author: G. Niegisch
Author: A. Necchi
Author: C.N. Sternberg
Author: S. Srinivas
Author: A. Alva
Author: U. Vaishampayan
Author: L. Cerbone
Author: M. Liontos
Author: J. Rosenberg
Author: T. Powles
Author: J. Belmunt
Author: M.D. Galsky

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×